Document:

EX-10.6

 Exhibit 10.6 

***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 

EXCLUSIVE SUPPLY AGREEMENT 
 This Supply
Agreement is entered between: 
 ERYtech Pharma S.A, a company incorporated under the laws of the Republic of France (no 479 560 013 RCS Lyon),
having its registered head office at Bâtiment Adenine, 60 avenue Rockefeller, 69008 Lyon, represented by Mr. Pierre-Olivier Goineau, Chief Operating Officer, 

hereinafter referred to as “ERYtech Pharma”. 

And, 
 Medac GmbH, a company having its
registered head office at Theaterstrasse 6, D22880 Wedel, Germany represented by Mr. Wilfried Mohr, Managing Director. 
 hereinafter
referred to as “Medac”. 
 hereinafter referred to individually or collectively as the “Parties” and individually as a
“Party”. 
 WHEREAS 
 WHEREAS, Medac
mainly promotes the development and marketing of therapeutics in the field of oncology and autoimmune diseases such as L-Asparaginase under the trademark medac (“Product” as defined below), and 

WHEREAS, ERYtech Pharma is developing a medicinal product under the trademark GRASPA® (“GRASPA®” as defined below) and consisting in L-asparaginase E-Coli encapsulated into red blood cells. The Product would be used as drug substance for the manufacture of GRASPA®. 
 WHEREAS ERYtech Pharma is interested in purchasing Products exclusively from Medac to manufacture
GRASPA® for use in next clinical trials and possible commercial sales of GRASPA®; and 

WHEREAS, Medac is willing to provide ERYtech Pharma with Products for the Purpose (as defined below). 

IN CONSEQUENCE WHEREOF THE PARTIES AGREE AS FOLLOWS: 

Article I. DEFINITIONS 
 For the purpose
of this Agreement, the following words and phrases shall have the following meanings: 
  

	1.1.	“Affiliate(s)” shall mean an entity or person which controls, is controlled by or is under common control with either Party. Control shall mean (a) the direct or indirect ownership of more
than one-half of the stock or participating shares entitled to vote for the election of directors of a corporation or a comparable ownership in any other type of entity, or 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A
CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	
(b) the power to direct the management and policies of an entity, whether by contract or otherwise. The terms “controlled by” or “under common control” shall have the
meanings correlative to the foregoing. 

  

	1.2.	“Agreement” shall mean this Supply Agreement, all amendments to this Agreement, and all exhibits to this Agreement. 

 

	1.3.	“Effective Date” shall mean on December 10th, 2008 

  

	1.4.	“Contract Year” means any twelve (12) month period ending on an anniversary of the Effective Date. 

  

	1.5.	“Confidential Information” shall mean all confidential and proprietary material and information received by one Party from the other Party or its Representative, including but not limited to:

  

	 	•	 	business and financial information; 

  

	 	•	 	methods of production, manufacturing and diagnostic testing; 

  

	 	•	 	unpublished results (i.e. text, graphics or numerical data) from scientific work; and 

  

	 	•	 	any other document or data received in written, printed, electronic, oral, or any other form. 

  

	1.6.	“Force Majeure” shall mean an occurrence which prevents, delays or interferes with the performance by a Party of any of its obligations hereunder, if such event occurs by reason of any act of
God, flood, or war, revolution, civil commotion, acts of public enemies, blockage or embargo, or any law, order or proclamation of any government, interruption of or delay in transportation, strike or labor disruption, or other cause beyond the
reasonable control of such Party. 

  

	1.7.	“Representatives” shall mean, with respect to a Party to this Agreement, the respective officers, directors, employees, and agents of such Party and of such Party’s Affiliates.

  

	1.8.	“GRASPA®” shall mean medicinal product consisting in L-asparaginase E-Coli encapsulated into human red blood cells. 

 

	1.9.	“Product” shall mean one unit ([***]) of L-Asparaginase ([***]) marketed by Medac under the trademark of medac together with its Documents (as defined below). [***]. 

 

	1.10.	“Specifications” shall mean the Product specifications and the packaging specifications set out in Exhibit 1. 

 

	1.11.	“Documents” shall mean the following documents prepared by the manufacturer of the Product: 

  

	 	•	 	Good Manufacturing Practices certificate and 

  

	 	•	 	A proof that the product used as source of L-asparaginase has granted a marketing authorization (MA) in at least one European country (copy of the license and Summary Product Characteristics for example) and

  

	 	•	 	The quality information (at least parts P.1, P.5, P.6 and P.8) of Medicinal Product as source of L-asparaginase or equivalent. 

  

	1.12.	“Regulatory Authority” means any federal, state, local or international regulatory agency, department, bureau or other governmental entity that is responsible for issuing any approvals (including
supplements, amendments, pre- and post-approvals and pricing approvals), licenses, registrations or authorizations of any national, supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other
governmental entity, necessary for the manufacture, distribution, use or sale of the Product in a regulatory jurisdiction. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	1.13.	“Third Party” shall mean any person other than a Party and such Party’s Representatives and Affiliates. 

Article II. PURPOSE OF THE AGREEMENT 

2.1. Purpose. The purpose of this Agreement is to set forth the terms and conditions under which Medac shall provide ERYtech Pharma with
Products to manufacture and to register GRASPA® for use anywhere in the world in its next clinical trials, and possible commercial sales of
GRASPA® directly or through license in all indications (hereinafter referred to as the “Purpose”). 

Article III. PURCHASE AND SALE 
 3.1.
Purchase and Sale. Subject to the terms and conditions set forth herein, Medac agrees to sell and ERYtech Pharma agrees to purchase Products exclusively from Medac in accordance with ERYtech Pharma’s purchase orders and this
Agreement. 
 3.2. Clinical use. As far as possible, Medac agrees to provide ERYtech Pharma with Products from the same batch. 

3.3. Forecast. ERYtech Pharma shall provide Medac with annually and quarterly rolling forecast of the quantities to be purchased as set out in
Exhibit 2 of which the first [***] shall be considered as binding orders. 
 3.4. Purchase Orders. Medac agrees that ERYtech Pharma shall
order the Products by facsimile or e-mail. Promptly after receipt of ERYtech Pharma order, Medac shall inform ERYtech Pharma of the acceptance of such order. After such acceptance, both Parties shall consider the order as binding (“Firm
Order”). Both Parties acknowledge that a Firm Order cannot be cancelled. 
 3.5. First Orders. Notwithstanding the Article 3.3 and the
Article 6.1, ERYtech Pharma orders on the Effective Date: 
  

	 	•	 	[***] Products for delivery later on [***] (from [***]); 

  

	 	•	 	[***] Products for delivery later on [***] (from [***]). 

 Other Products ordered shall be subject to the
Agreement (such as Article 3.3 and Article 6.1 without limitation) 
 3.6. Non-Conforming Orders. Medac will use reasonable commercial efforts
to fill non-conforming purchase orders for Products in accordance with ERYtech Pharma’s requests. 
 Article IV. PRICES AND
EXCLUSIVITY 
 4.1. Price. ERYtech Pharma shall purchase the Product and Medac will supply it with the terms and conditions of [***].
Except as provided in Article 4.2, the price for one (1) Product is [***] Euros up to [***] Product purchased per year. From the [***] Products purchased per year, the price for one (1) Product shall be [***] Euros. 

[***]. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 4.2. Exclusivity. In consideration of exclusivity in favour of Medac, Medac agrees to supply a
limited number of Products at the price of [***] Euros instead of those set out in Article 4.1. 
 This reduced price shall apply to [***] provided that
these Products for such purpose shall be limited to [***]. 
 The Products exceeding this cap shall be paid by ERYtech Pharma at the price as set out in
Article 4.1. 
 4.3. Limitation of exclusivity. ERYtech Pharma shall not be liable for exclusivity: 

 

	 	•	 	In a country, if the regulatory authority of this country prevents ERYtech Pharma from developing GRASPA® and/or slows down its development due to the Product;

  

	 	•	 	In case of multiple failures noticed by ERYtech Pharma and communicated to and agreed by the steering committee with no commitment by Medac to remedy them. 

Article V. PAYMENT 
 5.2. Invoicing
of the Products and Payment. Medac shall invoice for Products upon delivery of the Products to ERYtech Pharma according to the price mentioned in the accepted Firm Order. ERYtech Pharma shall pay to Medac the price of the Products within
[***] days of the date of the corresponding invoice and ERYtech Pharma shall pay for the Products by bank transfer on Medac’s bank account. 

Article VI. DELIVERIES 
 6.1.
Shipment. Except as set out in Article 3.5, Medac shall ship, directly or through any Third Party, Product to ERYtech Pharma to the delivery destination(s) specified in ERYtech Pharma’s purchase orders within [***] days following the
Firm Order. As long as the purchase orders are in compliance with the Forecast as defined under Article 3.3 
 However, if [***] Products are exceeding the
quarterly forecast as set out in Article 3.3 and if Medac will not be able to supply from existing stock without disturbing the supply obligations for other countries, ERYtech Pharma agrees to concede to Medac a lead-time of [***] from the Firm
Order acceptance provided that Medac informs ERYtech Pharma promptly after receipt of ERYtech Pharma order disturbing the supply obligations for other countries. 

6.2. Title and Risk of Loss. Risk of loss with respect to the Product shall pass to ERYtech Pharma in accordance [***] as defined in the
INCOTERMS and title shall pass to ERYtech Pharma at the same time risk of loss passes. 
 6.3. Packaging for Shipment. Unless otherwise agreed
in advance, all Products shall be packed by Medac as Medac reasonably deems appropriate to minimize risk of loss or damage in transit. 

Article VII. SPECIFICATIONS AND QUALITY CONTROL 

7.1. Specifications. Medac shall provide ERYtech Pharma with the Product in accordance with the Specifications and all applicable federal, state
and local laws and regulations. 
 Products must be packaged and labelled in accordance with all applicable standards of quality and all other requirements
of any Federal, State or local government statues, by-laws, regulations, standards or codes and any applicable voluntary standards and codes and general industry practice. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 7.2. Quality Assurance. Medac shall be responsible for ensuring that the Products meet
Medac’s internal quality assurance tests and procedures prior to shipment hereunder. 
 Article VIII. REGULATORY ASSISTANCE 

8.1. Regulatory approval and requests. Medac shall cooperate with ERYtech Pharma in connection with obtaining regulatory approval such as import
license and responding to any regulatory requests relating to the quality control of the GRASPA®. 

8.2. Regulatory submissions. ERYtech Pharma shall do its reasonable efforts to inform Medac of any regulatory submissions of GRASPA®. 
 Article IX. ADVERSE EVENTS AND RECALL 

The Parties shall handle the notification of adverse events and the recall of any Product pursuant to the specifications of the Regulatory Authorities and
duly inform each other of any adverse events. 
 Article X. STEERING COMMITTEE 

10.1. Composition of the Steering Committee. Each Party shall appoint one Representative to participate on a steering committee (the
“Steering Committee”). The Steering Committee shall meet via teleconference at least once a quarter during the term of this Agreement if not otherwise agreed. A precise agenda shall be drawn up before each meeting of the Steering
Committee. 
 10.2. Role. The specific role of the Steering Committee is to draw up the reports on the performance of the Agreement, outlining
the results obtained, to decide on the adaptations or modifications of the Agreement which may appear necessary or useful. 
 10.3.
Responsibilities. The Steering Committee shall be responsible for addressing any disputes that may arise between the Parties in connection therewith. In the event that the Steering Committee is unable to resolve any dispute, and a Party
wishes to pursue such dispute further, each such dispute shall be finally resolved by binding arbitration in accordance with the provisions set forth in Section 16.2. 

10.4. Representatives. At the time of execution of this Agreement, ERYtech Pharma’s Representative in the Steering Committee shall be [***]
and those of Medac shall be [***]. Each Party may, from time to time, replace its representative by written notice to the other Party specifying the prior representative and the replacement. 

Article XI. CONFIDENTIALITY 
 11.1.
Confidentiality. Each Party (i) shall maintain the other Party’s Confidential Information strictly confidential, (ii) agrees that it will take the same steps to protect the confidentiality of the

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 
other Party’s Confidential Information as it takes to protect its own Confidential Information, which shall in no event be less than reasonable steps, and (iii) shall not use the other
Party’s Confidential Information for any purpose other than in accordance with this Agreement and shall not disclose such Confidential Information to any person other than its personnel who have a need to know such Confidential Information for
the Purpose of this Agreement and who are subject to a nondisclosure obligation comparable in scope to this Section 11. 
 11.2.
Exceptions. The confidentiality obligations included in this Section shall not apply to information which a Party can clearly demonstrate: 
  

	 	•	 	is in the public domain prior to the date of disclosure or is subsequently disclosed to the public through no fault or act of the receiving Party; 

 

	 	•	 	is rightfully obtained by a receiving Party from a Third Party not obligated to preserve its confidentiality who did not receive the material or information directly or indirectly from the disclosing Party;

  

	 	•	 	is independently developed by the receiving Party without use of any Confidential Information of the disclosing Party; and 

  

	 	•	 	was lawfully in the receiving Party’s possession prior to obtaining it from the disclosing Party, as shown by pre-existing records. 

11.3. Authorized Disclosures. A receiving Party also may disclose Confidential Information of the disclosing Party to the extent required by a
court or by Regulatory Authority, provided that the receiving Party (a) gives the disclosing Party reasonable prior notice of the disclosure; (b) uses reasonable efforts to resist disclosing the Confidential Information; and
(c) cooperates with the disclosing Party on request to obtain a protective order or otherwise limit the disclosure. 
 11.4. No implied
Rights. It is agreed that except to the extent expressly provided otherwise herein disclosure of Confidential Information hereunder shall not constitute any grant, option or license under any patent, technology or others rights in or to such
Confidential Information. 
 Article XII. WARRANTY 

12.1. Product Warranty. [***] 
 12.2.
Remedies. ERYtech Pharma shall be obliged to inspect, examine and analyse the Products immediately upon receipt. In the event that a Product does not comply with the product warranty set out in Section 12.1 and such non-conforming
Product is returned to Medac by ERYtech Pharma freight prepaid, Medac will as soon as possible replace such non-conforming Product at no additional charge to ERYtech Pharma; the replaced Product will be returned to ERYtech Pharma, freight prepaid.

 However, ERYtech Pharma shall inform Medac within [***] after receipt of the Products of apparent defects in quality or quantity in writing. Failure or
delay shall mean acceptance of the delivered products and waiver any potential rights ERYtech may have with respect to the delivered Products. ERYtech shall inform medac within [***] in case he discovers any hidden defects. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 12.3. Use of the Products. ERYtech Pharma warrants to Medac that all the Products purchased by
ERYtech Pharma shall be used only to manufacture GRASPA®, in accordance with the provisions set forth in Section 2.1. ERYtech Pharma has not the right to import, promote, sell and
distribute the Product for any purpose. 
 Article XIII. INDEMNIFICATION 

13.1. Medac shall indemnify, defend and hold harmless ERYtech Pharma against any and all claims, liabilities, losses, costs and expenses arising out of
(i) any third party claims relating to the Product(s), except to the extent due to the negligence or misconduct of ERYtech Pharma in handling such Product(s), (ii) any breach by Medac of its obligations under this Supply Agreement, and
(iii) any negligence or unlawful act of Medac. 
 13.2. ERYtech Pharma shall indemnify, defend and hold harmless Medac against any and all
claims, liabilities, losses, costs and expenses arising out of (i) any third party claims relating to GRASPA® and/or the Product(s) due to the negligence or misconduct of ERYtech Pharma
in handling such Product(s), (ii) any breach by ERYtech of its obligations under this Supply Agreement, and (iii) any negligence or unlawful act of ERYtech Pharma. 

Article XIV. INSURANCE 
 14.1.
During the term of this Agreement, each Party agrees to procure and maintain, at its expense, insurance by a reputable company adequate to cover its obligations under this Agreement. 

14.2. Prior to or on the Effective Date, each Party will provide the other with a certificate of insurance evidencing the coverage set forth in this
Section 14.2 and thereafter shall provide the other Party such a certificate of insurance upon request. Each Party will provide the other with written notice at least [***] days prior to the cancellation, non-renewal or material change in such
insurance which materially adversely affects the rights of the other Party hereunder. 
 Article XV. TERM AND TERMINATION 

15.1. Term. The term of this Agreement shall commence upon the Effective Date and unless terminated earlier or extended pursuant to this
Agreement shall expire twenty (20) years thereafter. 
 15.2. Termination. The Agreement may be terminated 

 

	 	a)	without notice and compensation by the mutual written agreement of the Parties; 

  

	 	b)	by either Party in the event a Party is in default of the terms and conditions of this Agreement and fails to remedy the default within [***] after receiving written notice specifying such default.

 15.3. Consequences of Termination. Except with respect to a termination by Medac pursuant to Section 15.2.b, the
expiration or termination of this Agreement will not relieve Medac from its obligation to provide with any Product ordered pursuant to the Agreement received prior to the effective date of such expiration or termination unless a hindrance occurs to
supply to ERYtech Asparaginase medac and/or medac will not [***]. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 Except with respect to a termination by ERYtech Pharma pursuant to Section 15.2.b, ERYtech Pharma will
pay Medac for Product(s) supplied in accordance with this Agreement prior to the effective date of expiration or termination of this Agreement. 
 Promptly
after the expiration or termination of this Agreement for any reason, the Parties will return to each other all tangible manifestations of each other’s Confidential Information at that time in the possession of either Party, or, with the
written permission of the other Party, destroy such items; provided that each Party may retain one (1) tangible manifestation of the other Party’s Confidential Information in its legal department for archival purposes. 

Expiration or termination of this Agreement will not relieve either Party of any liability having accrued hereunder prior to the effective date of such
expiration or termination. 
 Termination and/or expiration of this Agreement by either Party does not entitle the other the Party to any indemnification or
compensation for any expenses incurred in the performance of the Agreement, loss of profit or any other reason unless otherwise provided in this Agreement. 

15.4. Survival. Upon expiration or termination of this Agreement, the obligations of the Parties under Sections 11, 12, 15.3, 16.1, 16.2 and
this Section 15.4, and any other section which by its nature is to survive, shall survive such expiration or termination. 
 Article
XVI. MISCELLANEOUS 
 16.1. Governing Law. This Agreement shall be governed by and construed according to the laws of [***], without
regard to its conflict of laws principles. 
 16.2. Dispute Resolution. The Parties shall make all reasonable efforts to amicably resolve any
disputes arising out of or relating to this Agreement. All disputes between the Parties arising from or relating to this Agreement or the breach hereof that cannot otherwise be resolved informally shall be conclusively settled by binding arbitration
in accordance with the Rules of Conciliation and Arbitration of the International Chamber of Commerce (“ICC”) in effect at the time the demand for arbitration is filed by the demanding party with the ICC, as supplemented by the further
requirements of this Section. 
 Such arbitration shall be conducted by three (3) arbitrators, with each Party selecting one arbitrator within thirty
(30) days after the serving of a statement of claim by the claimant on the respondent, and the two (2) selected arbitrators selecting a mutually agreeable third arbitrator within thirty (30) days thereafter from a list of qualified
potential arbitrators provided by the ICC, or if such arbitrators are unable to select such third arbitrator within such time period, a third arbitrator appointed by the ICC promptly thereafter. The place of Arbitration shall be [***] in the English
language and the award shall be rendered in [***]. The decision of the arbitrators shall be final and conclusive and shall be binding upon the Parties. By agreeing to arbitration, the Parties do not intend to deprive any court of its jurisdiction to
issue a pre-arbitral injunction, pre-arbitral attachment, or other order in aid of arbitration proceedings and the enforcement of any award. Without prejudice to such provisional remedies as may be available under the jurisdiction of a court, the
arbitral tribunal shall have full authority to grant provisional remedies or to order any Party or Parties to request that a court modify or vacate any temporary or preliminary relief issued by that court, and to award damages for the failure of any
Party to comply with the arbitral tribunal’s orders to that effect. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 16.3. Notices. All notices sent under this Agreement shall be in writing and (i) hand
delivered; (ii) transmitted by legible telecopy with a copy sent concurrently by certified mail, return receipt requested; or (iii) delivered by prepaid priority delivery service. Notices shall be sent to the Parties at the following
addresses or such other addresses as the Parties subsequently may provide: 
 If to ERYtech Pharma 

ERYtech Pharma 
 60 Avenue Rockefeller 

Bâtiment Adenine 
 69008 Lyon 

France 
 Phone: [***] 

Fax: [***] 
 Email: [***] 

If to Medac: 
 Medac GmbH 

[***] 
 Theaterstrasse ,6 

22880 Wedel 
 Germany 

Phone: [***] 
 Fax: [***] 

Email: [***] 
 A Party may change its address or numbers of
service by notice to the other party. 
 16.4. Force Majeure. Neither Party shall be liable to the other for the failure to perform, or a
delay in performing, its obligations under this Agreement by virtue of the occurrence of an event of Force Majeure. The Party affected by such Force Majeure event shall promptly notify the other Party and shall exert reasonable efforts to eliminate,
cure or overcome such Force Majeure event and to resume performance of its obligations hereunder. 
 In the event a Force Majeure event affecting either
Party hereunder continues for more than six (6) months the Party not subject to the Force Majeure event may terminate this Agreement upon written notice without further obligations. 

16.5. Cumulative Remedies. The rights and remedies provided in this Agreement and all other rights and remedies available to either Party at law
or in equity are, to the extent permitted by law, cumulative and not exclusive of any other right or remedy now or hereafter available at law or in equity. Neither asserting a right nor employing a remedy shall preclude the concurrent assertion of
any other right or employment of any other remedy, nor shall the failure to assert any right or remedy constitute a waiver of that right or remedy. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 16.6. Amendment. This Agreement may be modified or amended only by written agreement of the
Parties. 
 16.7. Entire Agreement. This Agreement (including any exhibits hereto, all of which are incorporated herein by reference)
constitutes the entire agreement between the Parties concerning the subject matter of this Agreement. This Agreement supersedes all prior agreements between the Parties concerning the subject matter of this Agreement. 

16.8. Independent Contractor. Medac is an independent contractor. Nothing in this Agreement is intended or shall be deemed to create an
association, partnership, joint venture, agency or employer and employee relationship between the Parties, or to authorize either Party to act as agent for the other or to enter into contracts on behalf of the other. 

16.9. Assignment. Neither Party shall assign to a Third Party any portion of this Agreement without the written approval of the other Party.

 16.10. Binding Effect. All the provisions thereof shall inure to the benefit of and be binding upon the Affiliates of the Parties. 

16.11. Use of Trademark. Each Party hereby agrees that neither it nor any of its Affiliates shall use the name, logo, or any other trademarks of
any other Party. Each Party agrees that it may use its own trademarks for any purpose without obligation to the other Party. 
 16.12.
Severability. The provisions of this Agreement are deemed to be several and any invalidity of any provision of this Agreement will not affect the validity of the remaining provisions of this agreement. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 IN WITNESS whereof, the Parties have caused this Agreement to be executed by their duly authorized
officers. 
  

					
	ERYtech Pharma	 		 	
	
	  

	Mr. Pierre-Olivier Goineau	 		 	Place and date:
	Chief Operating Officer	 		 	Lyon, December 10th 2008
			
	Signature	 		 	/s/ Pierre-Olivier Goineau
			
	Medac	 		 	
	
	  

	Wilfred Mohr	 		 	Place and date:
	Managing Director	 		 	Wedel, Dec. 12th, 2008
			
	Signature	 		 	/s/ Wilfred Mohr
			
	Medac	 		 	
	
	  

	Ppa. Dr. Ulrich Kosciessa	 		 	Place and date:
	(Director of medac International)	 		 	Wedel, Dec. 12th, 2008
			
	Signature	 		 	/s/ ppa. Dr. Ulrich Kosciessa

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 EXHIBIT 1: SPECIFICATIONS 

Release specification Asparaginase [***] 
  

			
	 Test parameter
	 	 Limit

	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 EXHIBIT 2: FORECASTS 

Maximum number of vials ordered for the [***] 

[***] : [***] vials 

[***] : [***] vials 

[***] : [***] vials 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 ADDENDUM NO 1 TO 

EXCLUSIVE SUPPLY AGREEMENT 
 This Addendum
is entered between: 
 ERYtech Pharma S.A, a company incorporated under the laws of the Republic of France (n° 479 560 013 RCS Lyon), having its
registered head office at Bâtiment Adenine, 60 avenue Rockefeller, 69008 Lyon, represented by Mr. Pierre-Olivier Goineau, Chief Operating Officer, 

hereinafter referred to as “ERYtech Pharma”. 

And, 
 Medac GmbH, a company having its
registered head office at Theaterstrasse 6, D22880 Wedel, Germany represented by Mr. Wilfried Mohr, Managing Director. 
 hereinafter
referred to as “Medac”. 
 hereinafter referred to individually or collectively as the “Parties” and individually as a
“Party”. 
 WHEREAS 
 The Parties have
signed an Exclusive Supply Agreement on December 10th, 2008 (hereinafter “the Agreement”). 
 The Parties wish to extend the Products
at reduced price. 
 Therefore, the Parties agree to modify the Article 4.2 of the Agreement set forth below. 

The Articles are hereby amended to read as follow: 
 4.2.
Exclusivity. In consideration of exclusivity in favour of Medac, Medac agrees to supply a limited number of Products at the price of [***] Euros instead of those set out in Article 4.1. 

This reduced price shall apply to Products used [***] provided that these Products for such purposes shall be limited to [***]. The Products exceeding this
cap shall be paid by ERYtech Pharma at the price as set out in Article 4.1. 
 Except as otherwise provided herein, all terms and conditions of the
Agreement shall remain in full force and effect. 
 IN WITNESS whereof, the Parties have caused this Addendum to be executed by their duly authorized
officers. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

					
	ERYtech Pharma	 		 	
	
	  

	Mr. Pierre-Olivier Goineau	 		 	Place and date:
	Chief Operating Officer	 		 	Lyon, July 31st 2009
			
	Signature	 		 	/s/ Pierre-Olivier Goineau
			
	Medac	 		 	
	
	  

	Wilfred Mohr	 		 	Place and date:
	Managing Director	 		 	Wedel, August 19th 2009
			
	Signature	 		 	/s/ Wilfred Mohr
			
	Medac	 		 	
	
	  

	Ppa. Dr. Ulrich Kosciessa	 		 	Place and date:
	Director of medac International	 		 	Wedel, August 12th 2009
			
	Signature	 		 	/s/ ppa. Dr. Ulrich Kosciessa

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.EX-10.7

 Exhibit 10.7 

***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 EXCLUSIVE SUPPLY AGREEMENT 

for recombinant L-Asparaginase 

THIS SUPPLY AGREEMENT is entered between ERYTECH
PHARMA S.A, a company incorporated under the laws of the Republic of France (no 479 560 013 RCS Lyon), having its registered head office at Bâtiment Adenine, 60 avenue Rockefeller, 69008 Lyon, France, represented by
Mr. Pierre-Olivier Goineau, Chief Executive Officer, (VAT No. FR 10479560013), hereinafter referred to as “ERYtech Pharma” and MEDAC GMBH, a company having its registered head
office at Theaterstrasse 6, D22880 Wedel, Germany represented by Nikolaus Graf Stolberg, Managing Director and Dr. Michaela Rehberg, Director Drug Regulatory Affairs/Pharmaceutical Development (VAT No. DE 118579535), hereinafter referred to as
“medac”, hereinafter referred to individually or collectively as the “Parties” and individually as a “Party”. 

WHEREAS, medac mainly promotes the development and marketing of therapeutics in the field of
oncology and autoimmune diseases such as L-Asparaginase under the trademark medac and is developing a new recombinant form of L-Asparaginase defined below as “Product” as well as other non cell based formulation(s) of recombinant
L-asparaginase; and 
 WHEREAS, ERYtech Pharma is developing a medicinal product under the trademark
GRASPA® (“GRASPA®” as defined below) consisting in E-coli L-asparaginase encapsulated into red blood cells. The
“Product” would be used as drug substance for the manufacture of GRASPA®; 

WHEREAS ERYtech Pharma is interested in purchasing “Product” exclusively from medac to
manufacture GRASPA® for use in next clinical trials and commercial sales of GRASPA®; and 

On December 10th, 2008, ERYtech Pharma and medac signed an exclusive supply
agreement for the supply of native E.coli L-Asparaginase by medac to ERYtech Pharma (the “Previous agreement”). The Parties agree to extend the supply to the “Product”. This
Agreement does not replace the Previous Agreement, which remains in effect and valid. 
 WHEREAS, medac
is willing to provide ERYtech Pharma with “Product” for the Purpose (as defined below). 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 IN CONSEQUENCE WHEREOF THE
PARTIES AGREE AS FOLLOWS: 
 ARTICLE I 

DEFINITIONS 
 For the
purpose of this Agreement, the following words and phrases shall have the following meanings: 
 1.1
“Affiliate(s)” shall mean an entity or person which controls, is controlled by or is under common control with either Party. Control shall mean (a) the direct or indirect ownership of more than one-half of the stock or
participating shares entitled to vote for the election of directors of a corporation or a comparable ownership in any other type of entity, or (b) the power to direct the management and policies of an entity, whether by contract or otherwise.
The terms “controlled by” or “under common control” shall have the meanings correlative to the foregoing. 
 1.2
“Agreement” shall mean this Supply Agreement, all amendments to this Agreement, and all exhibits to this Agreement. 

1.3 “Effective Date” shall mean April 6th, 2011. 

1.4 “Confidential Information” shall mean all confidential and proprietary material and information received by
one Party from the other Party or its Representative, including but not limited to: 
  

	 	•	 	business and financial information; 

  

	 	•	 	methods of production, manufacturing and diagnostic testing; 

  

	 	•	 	unpublished results (i.e. text, graphics or numerical data) from scientific work; and 

  

	 	•	 	any other document or data received in written, printed, electronic, oral, or any other form. 

1.5 “Force Majeure” shall mean an occurrence which prevents, delays or interferes with the performance by a
Party of any of its obligations hereunder, if such event occurs by reason of any act of God, flood, or war, revolution, civil commotion, acts of public enemies, blockage or embargo, or any law, order or proclamation of any government, interruption
of or delay in transportation, strike or labor disruption, or other cause beyond the reasonable control of such Party. 
 1.6
“Representatives” shall mean, with respect to a Party to this Agreement, the respective officers, directors, employees, and agents of such Party and of such Party’s Affiliates. 

1.7 “GRASPA®” shall mean medicinal product
consisting suspension of erythrocytes encapsulating recombinant L-asparaginase and released by ERYtech Pharma. 
 1.8
“API” shall mean Active Pharmaceutical Ingredient – [recombinant asparaginase produced of behalf of medac and used to produce the Product]. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 1.9 “Product” shall mean one vial of ([***]) of recombinant
L-Asparaginase, in the form of a powder for injection produced packed and labeled by or on behalf of Medac and released by Medac according to information contained in “Documents” (as defined below) and applicable cGMP. 

1.10 “Specifications”: A list of tests, references to analytical procedures, and appropriate acceptance
criteria that are numerical limits, ranges or other criteria for the test(s) described as amended from time to time to comply with regulatory requirements. It establishes the set of criteria to which a material should conform to be considered
acceptable for its intended use. “Conformance to Specification” means that the material, when tested according to the listed analytical procedures, will meet the listed acceptance criteria as outlined in the Documents. 

1.11 “Documents” shall mean the current version for the following documents prepared by Medac: Documentation
regarding quality and clinical safety information of Product and API (such as Quality documentation of the Investigational Medicinal Product Dossier (IMPD) in its current version, clinical/safety information on the Product (parts 6 and 7 of the
investigator brochure on the Product) and regulatory background information (briefing document) in its current version as well as GMP certificates, manufacturing licences or import permits etc) provided by MEDAC to ERYTECH in order to complete
relevant part of regulatory submissions filed in order to grant clinical trial authorization for GRASPA manufactured from the Product. 

1.12 “Regulatory Authority” means any federal, state, local or international regulatory agency, department,
bureau or other governmental entity such as the Food & Drug Administration (“FDA”) and/or by the European Medicines Agency (“EMA”), that is responsible for issuing any approvals (including supplements, amendments, pre-
and post-approvals and pricing approvals), licenses, registrations or authorizations of any national, supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity, necessary for the
manufacture, distribution, use or sale of the Product in a regulatory jurisdiction. 
 1.13 “Third Party”
shall mean any person other than a Party and such Party’s Representatives and Affiliates. 
 1.14
“GRASPA”-Indications shall mean the indications as specified and agreed in Exhibit 3 to this agreement. 

1.15 “Clinical Supply” shall mean the supply of “Product” by medac to ERYtech Pharma for the purpose
of setting up clinical trials with GRASPA® anywhere in the world and sponsored by ERYtech Pharma in GRASPA® Indications as specified
and agreed in Exhibit 3 to this Agreement. 
 1.16 “Routine Supply” shall mean the supply of
“Product” by medac to ERYtech Pharma for the purpose of selling GRASPA anywhere in the world pursuant to a Marketing Authorization. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 1.17 “Marketing Authorization” shall mean any marketing
authorizations agreed by the Regulatory Authorities for the sale of GRASPA® in a regulatory jurisdiction. 

ARTICLE II 
 PURPOSE OF
THE AGREEMENT 
 2.1 Purpose. The purpose of this Agreement is to set forth the terms and conditions under which medac
shall provide ERYtech Pharma with “Product” to manufacture and to register GRASPA® for use anywhere in the world in its next clinical trials, and possible commercial sales of GRASPA® directly or through license in “GRASPA® Indications” (hereinafter referred to as the “Purpose”). 

ARTICLE III 
 PURCHASE
AND SALE 
 3.1 Purchase and Sale. Subject to the terms and conditions set forth herein, medac agrees to sell Product,
which shall only be used in erythrocytes encapsulated L-Asparaginase, exclusively to ERYtech Pharma and ERYtech Pharma agrees to purchase Product exclusively from medac in accordance with ERYtech Pharma’s purchase orders under this Agreement.
For clarification, the exclusivity to sell the Product shall only apply in connection with the above mentioned Purpose and with the Article 4.2. 

3.2 Clinical Supply. medac agrees to provide ERYtech Pharma with Product from the same batch if possible for each clinical
trial. 
 3.3 Forecast. For Routine Supply ERYtech Pharma shall provide medac with annually and quarterly rolling forecast of
the quantities to be purchased as set out in Exhibit 2 of which the first [***] shall be considered as binding orders and additional [***] as non-binding. In case the future agreed order period between medac and the manufacturer is longer, this
order period shall be adapted accordingly. For Clinical Supply the binding forecast is attached as Exhibit 2, which shall be treated as binding order, too. 

3.4 Purchase Orders. For Routine Supply medac agrees that ERYtech Pharma shall order the Product by facsimile or e-mail.
Promptly after receipt of ERYtech Pharma order, medac shall inform ERYtech Pharma of the acceptance of such order. After such acceptance, both Parties shall consider the order as binding (“Firm Order”). Both Parties
acknowledge that a Firm Order cannot be cancelled. 
 3.5 Non-Conforming Orders. medac will use reasonable commercial efforts
to fill non-conforming purchase orders for Product in accordance with ERYtech Pharma’s requests. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 ARTICLE IV 

PRICES AND EXCLUSIVITY 

4.1 Price. ERYtech Pharma shall purchase the Product and medac will supply the Product with the terms and conditions of the [***]. 

4.1.1 Clinical Supply. The price for supply will be: 

Pilot scale: [***] € [***] / vial 

Norm scale: Approximately € [***] / vial, whereby the final price will be determined by the Parties in good faith once the development of
the norm scale process is finalised, however no later than [***] (hereinafter referred to as “Norm scale price”). 

This is the price for clinical trial purposes only. At the request of medac the Norm scale price could be rediscussed between the Parties
[***] following the final determination of the Norm scale price. If justified by industrial cost increases it could be revised and increased up to a maximum of [***]. This price will remain for the next [***]. At the end of this period ([***] from
date of signature of the Agreement) a new discussion between the parties will redefined the new Norm scale price for the next [***]. 

medac shall inform ERYtech Pharma about the change from Pilot Scale into Norm Scale [***] in advance. 

4.1.2 Routine Supply. The price for Routine Supply will be agreed upon between both parties once the development of the Product has
been finalized, however, not higher than the Norm scale price. 
 In any case, the Parties agree that the price for routine supply will be
negotiated, in good faith, according to the market and to the market price of recombinant L-Asparaginase. 
 4.2 Exclusivity Field.

 The Supply Agreement covers all territories of the world and all GRASPA®
Indications. ERYtech Pharma shall buy from medac the Product for the term of this Agreement and for as long as medac can deliver at competitive price. 

For the avoidance of doubt: 
  

	 	•	 	medac shall have the right to develop non-cell based formulation of recombinant L-asparaginase in any indication 

  

	 	•	 	ERYtech Pharma will have the right to develop GRASPA®, manufactured with the Product, in all GRASPA®
Indications. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 4.3 Limitation of exclusivity. ERYtech Pharma shall not be liable for exclusivity:

  

	 	•	 	In a country, if the regulatory authority of this country prevents ERYtech Pharma from developing GRASPA® and/or slows down its development due to the Product;

  

	 	•	 	In case of repeated failures noticed by ERYtech Pharma and communicated to and agreed by the steering committee with no commitment by medac to remedy them. 

ARTICLE V 

NON-COMPETITION 
 ERYtech
Pharma shall be entitled to market GRASPA®, manufactured with the Product, in all territories, to treat patients in all indications as defined in Exhibit 3: 

 

	 	•	 	in second line; 

  

	 	•	 	in first line as long as the non cell based formulation of recombinant L-Asparaginase developed by medac: 

  

	 	•	 	is not registered in first line in a territory, in an indication or; 

  

	 	•	 	cannot be prescribed in first line by clinician for medical reason, case by case, in an indication in a territory. 

[***] 
 [***] 

[***] 
 For the avoidance of any
doubt, the Parties do not give a right to distribute the Product or GRASPA®. 

Notwithstanding the above-mentioned, ERYtech Pharma shall not be liable in case of any unsolicited off-labelling sales of GRASPA®. 
 ARTICLE VI 

PAYMENT 
 6.1 Invoicing
of the Product and Payment. medac shall invoice for Product upon delivery of the Product to ERYtech Pharma according to the price mentioned in the accepted Firm Order. ERYtech Pharma shall pay to medac the price of the Product within [***] days
of the date of the corresponding invoice and ERYtech Pharma shall pay for the Products by bank transfer on medac’s bank account. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 ARTICLE VII 

DELIVERIES 
 7.1
Shipment. Except as set out in Article 3.5, medac shall ship, directly or through any Third Party, Product to ERYtech Pharma to the delivery destination(s) specified in ERYtech Pharma’s purchase orders within [***] days following the Firm
Order. As long as the purchase orders are in compliance with the Forecast as defined under Article 3.3. 
 7.2 Title and Risk of
Loss. Risk of loss with respect to the Product shall pass to ERYtech Pharma in accordance with [***] as defined in the INCOTERMS and title shall pass to ERYtech Pharma at the same time risk of loss passes. 

7.3 Packaging for Shipment. Unless otherwise agreed in advance, Product shall be packed by medac as medac reasonably deems appropriate
to minimize risk of loss or damage in transit. 
 7.4 Delivery reliability. 

For the Clinical Supply and for the Routine Supply for the Acute Lymplopblastic Leukemia market, medac shall store the Product for a [***]
rolling supply based on the annual forecast linked to the total development forecast based on the plan specified in Exhibit 2 as security stock. The annual forecast for the Routine Supply in other indications shall be negotiated in good faith
between the Parties. 
 In return ERYtech shall be obliged to purchase such security stock on the agreed terms in total and conditions prior
to expiration of such security stock. Furthermore, should medac encounter production problems beyond such [***] storage, then medac shall deliver to all customers with, percentage wise, equal reduction compared to the forecasts of the respective
customers. 
 ARTICLE VIII 

QUALITY AGREEMENT 
 The
Parties agree to sign a quality agreement (the “Quality Agreement”) at the same time as signing this Agreement. 

The purpose is to establish the Quality Agreement between the two companies with regards to the quality of the Product that will be supplied
by medac to ERYtech Pharma in view to manufacture clinical trials batches of GRASPA®. 

This Quality Agreement takes the form of a detailed checklist including the activities associated with pharmaceutical manufacturing, testing
and supply of Product for ERYtech Pharma. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 In case of inconsistency between the Supply Agreement and the Quality Agreement, the Supply
Agreement prevails. 
 ARTICLE IX 

REGULATORY ASSISTANCE 

The Parties agree to sign a regulatory agreement (the “Regulatory Agreement”) at the same time as
signing this Agreement. 
 In case of inconsistency between the Supply Agreement and the Regulatory Agreement, the Supply
Agreement prevails. 
 The purpose of the regulatory agreement is to describe the co-operation between medac as the responsible owner of the
Product and ERYtech Pharma as the responsible sponsor and future Marketing Authorization Holder for GRASPA®. 

In order to ensure an effective processing of regulatory activities, it is important to determine the responsibilities of medac and Erytech as
well as to lay down the sequence of actions within the development and registration process of GRASPA and if related to Product as well. 

This Agreement takes the form of a detailed checklist including the activities and responsibilities associated with these submissions. 

ARTICLE X 
 ADVERSE
EVENTS AND RECALL 
 The Parties agree to sign a drug safety agreement (the “Drug Safety
Agreement”) at the same time as signing this Agreement. 
 In case of inconsistency between the Supply Agreement
and the Drug Safety Agreement, the Supply Agreement prevails. 
 The Parties shall handle the notification of adverse events and the recall
of any Product pursuant to the specifications of the Regulatory Authorities and duly inform each other of any adverse events. 
 ARTICLE
XI 
 STEERING COMMITTEE 

11.1 Composition of the Steering Committee. Each Party shall appoint one Representative to participate on a steering committee (the
“Steering Committee”). The Steering Committee shall meet via teleconference at least once a quarter during the term of this Agreement if not otherwise agreed. A precise agenda shall be drawn up before each
meeting of the Steering Committee. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 11.2 Role. The specific role of the Steering Committee is to draw up the reports on
the performance of the Agreement, outlining the results obtained, to decide on the adaptations or modifications of the Agreement which may appear necessary or useful. 

11.3 Responsibilities. The Steering Committee shall be responsible for addressing any disputes that may arise between the Parties in
connection therewith. In the event that the Steering Committee is unable to resolve any dispute, and a Party wishes to pursue such dispute further, each such dispute shall be finally resolved by binding arbitration in accordance with the provisions
set forth in Section 17.3. 
 11.4 Representatives. At the time of execution of this Agreement, ERYtech Pharma’s
Representative in the Steering Committee shall be [***] and those of Medac shall be [***]. Each Party may, from time to time, replace its representative by written notice to the other Party specifying the prior representative and the replacement.

 ARTICLE XII 

CONFIDENTIALITY 
 12.1
Confidentiality. Each Party (i) shall maintain the other Party’s Confidential Information strictly confidential, (ii) agrees that it will take the same steps to protect the confidentiality of the other Party’s Confidential
Information as it takes to protect its own Confidential Information, which shall in no event be less than reasonable steps, and (iii) shall not use the other Party’s Confidential Information for any purpose other than in accordance with
this Agreement and shall not disclose such Confidential Information to any person other than its personnel who have a need to know such Confidential Information for the Purpose of this Agreement and who are subject to a nondisclosure obligation
comparable in scope to this Section 12. 
 12.2 Exceptions. The confidentiality obligations included in this Section
shall not apply to information which a Party can clearly demonstrate: 
  

	 	•	 	is in the public domain prior to the date of disclosure or is subsequently disclosed to the public through no fault or act of the receiving Party; 

 

	 	•	 	is rightfully obtained by a receiving Party from a Third Party not obligated to preserve its confidentiality who did not receive the material or information directly or indirectly from the disclosing Party;

  

	 	•	 	is independently developed by the receiving Party without use of any Confidential Information of the disclosing Party; and 

  

	 	•	 	was lawfully in the receiving Party’s possession prior to obtaining it from the disclosing Party, as shown by pre-existing records. 

12.3 Authorized Disclosures. A receiving Party also may disclose Confidential Information of the disclosing Party to the extent
required by a court or by Regulatory Authority, 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 
provided that the receiving Party (a) gives the disclosing Party reasonable prior notice of the disclosure; (b) uses reasonable efforts to resist disclosing the Confidential
Information; and (c) cooperates with the disclosing Party on request to obtain a protective order or otherwise limit the disclosure. 

12.4 No implied Rights. It is agreed that except to the extent expressly provided otherwise herein disclosure of Confidential
Information hereunder shall not constitute any grant, option or license under any patent, technology or others rights in or to such Confidential Information. 

ARTICLE XIII 
 WARRANTY

 13.1 Declaration. medac declares to ERYtech Pharma that [***] 

13.2 Remedies. ERYtech Pharma shall be obliged to inspect, examine and analyse the Products immediately upon receipt. In the event that
a Product does not comply with the product declaration set out in Section 13.1 and such non-conforming Product is returned to medac by ERYtech Pharma freight prepaid, medac will as soon as possible replace such non-conforming Product at no
additional charge to ERYtech Pharma; the replaced Product will be returned to ERYtech Pharma, freight prepaid. 
 However, ERYtech
Pharma shall inform medac within [***] after receipt of the Products of hidden defects in writing. Failure or delay shall mean acceptance of the delivered products and waiver any potential rights ERYtech Pharma may have with respect to the delivered
Products. ERYtech Pharma shall inform medac within [***] in case he discovers any apparent defects. 
 13.3 Use of the Products.
ERYtech Pharma warrants to medac that all the Products purchased by ERYtech Pharma shall be used only to manufacture GRASPA®, in accordance with the provisions set forth in Section 2.1.
ERYtech Pharma has not the right to import, promote, sell and distribute the Product for any other purpose. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 ARTICLE XIV 

INDEMNIFICATION 
 14.1
medac shall indemnify, defend and hold harmless ERYtech Pharma against any and all claims, liabilities, losses, costs and expenses arising out of (i) any Third Party claims relating to the Product(s), except to the extent due to the
negligence or misconduct of ERYtech Pharma in handling such Product(s), (ii) any violation by medac of third party intellectual property rights (iii) any breach by medac of its obligations under this Supply Agreement, and (iv) any
negligence or unlawful act of medac. 
 14.2 ERYtech Pharma shall indemnify, defend and hold harmless medac against any and
all claims, liabilities, losses, costs and expenses arising out of (i) any Third Party claims relating to GRASPA® and/or the Product(s) - except to the extent due to the negligence or
misconduct of medac in handling such Product(s) (ii) any violation by ERYtech Pharma of third party intellectual property rights, (iii) any breach by ERYtech of its obligations under this Supply Agreement, and (iv) any negligence or
unlawful act of ERYtech Pharma. 
 ARTICLE XV 

INSURANCE 
 15.1
During the term of this Agreement, each Party agrees to procure and maintain, at its expense, insurance by a reputable company adequate to cover its obligations under this Agreement. 

15.2 Prior to or on the Effective Date, each Party will provide the other with a certificate of insurance evidencing the coverage set
forth in this Section 15 and thereafter shall provide the other Party such a certificate of insurance upon request. Each Party will provide the other with written notice at least thirty (30) days prior to the cancellation, non-renewal or
material change in such insurance which materially adversely affects the rights of the other Party hereunder. 
 ARTICLE XVI

 TERM AND TERMINATION 

16.1 Term. The term of this Agreement shall commence: 
  

	 	•	 	For the Clinical Supply; upon the Effective Date and shall continue for a period of ten (10) years; 

  

	 	•	 	For the Routine Supply; upon the first Routine Supply and shall continue for a period of five (5) years unless earlier terminated pursuant to the provision 16.2. 

This Agreement will automatically and continuously be renewed for a period of subsequent [***], unless terminated with [***] notice period to
the then running agreement term. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 16.2 Termination. The Agreement may be terminated: 

(a) without notice and compensation by the mutual written agreement of the Parties. 

(b) by either Party in the event a Party is in default of the terms and conditions of this Agreement and fails to remedy the default
within [***] after receiving written notice specifying such default. 
 (c) without notice and compensation by either party in case
of non-authorization of the Product by the Regulatory Authorities. 
 (d) without notice and compensation in case of non-agreement on
the Price for the Routine Supply. 
 16.3 Consequences of Termination. Except with respect to a termination by medac pursuant to
Section 16.2.b), the expiration or termination of this Agreement will not relieve medac from its obligation to provide with any Product ordered pursuant to the Agreement received prior to the effective date of such expiration or termination.

 Promptly after the expiration or termination of this Agreement for any reason, the Parties will return to each other all tangible
manifestations of each other’s Confidential Information at that time in the possession of either Party, or, with the written permission of the other Party, destroy such items; provided that each Party may retain one (1) tangible
manifestation of the other Party’s Confidential Information in its legal department for archival purposes. 
 Expiration or termination
of this Agreement will not relieve either Party of any liability having accrued hereunder prior to the effective date of such expiration or termination. 

In order to compensate for the [***], ERYtech Pharma shall be entitled to the following damages [***], or [***], do not [***] and/or if the
[***]. 
 In addition to any other [***], the damages owed [***] as above shall be [***]: 

 

	 	•	 	[***] 

  

	 	•	 	[***]. 

 These damages will [***] upon [***]. 

16.4 Survival. Upon expiration or termination of this Agreement, the obligations of the Parties under Sections 12, 13, 16.3, 17.1,
17.2, 17.3 and this Section 16.4, and any other section which by its nature is to survive, shall survive such expiration or termination. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 ARTICLE XVII 

MISCELLANEOUS 
 17.1
Governing Law. This Agreement shall be governed by and construed according to the laws of [***], without regard to its conflict of laws principles. 

17.2 Regulatory Rules. This Agreement shall be executed in accordance with all applicable rules issued by the Regulatory Authorities
(such as regulations, policies or guidelines), of which both Parties acknowledge their prevalence over the Agreement. 
 17.3
Dispute Resolution. The Parties shall make all reasonable efforts to amicably resolve any disputes arising out of or relating to this Agreement. All disputes between the Parties arising from or relating to this Agreement or the breach hereof
that cannot otherwise be resolved informally within sixty (60) days after referral to the CEO of medac and the CEO of ERYtech Pharma, shall be conclusively settled by binding arbitration in accordance with the Rules of Conciliation and
Arbitration of the International Chamber of Commerce (“ICC”) in effect at the time the demand for arbitration is filed by the demanding party with the ICC, as supplemented by the further requirements of this
Section. 
 Such arbitration shall be conducted by three (3) arbitrators, with each Party selecting one arbitrator within thirty
(30) days after the serving of a statement of claim by the claimant on the respondent, and the two (2) selected arbitrators selecting a mutually agreeable third arbitrator within thirty (30) days thereafter from a list of qualified
potential arbitrators provided by the ICC, or if such arbitrators are unable to select such third arbitrator within such time period, a third arbitrator appointed by the ICC promptly thereafter. The place of Arbitration shall be [***] in the English
language and the award shall be rendered in [***]. The decision of the arbitrators shall be final and conclusive and shall be binding upon the Parties. By agreeing to arbitration, the Parties do not intend to deprive any court of its jurisdiction to
issue a pre-arbitral injunction, pre-arbitral attachment, or other order in aid of arbitration proceedings and the enforcement of any award. Without prejudice to such provisional remedies as may be available under the jurisdiction of a court, the
arbitral tribunal shall have full authority to grant provisional remedies or to order any Party or Parties to request that a court modify or vacate any temporary or preliminary relief issued by that court, and to award damages for the failure of any
Party to comply with the arbitral tribunal’s orders to that effect. 
 17.4 Notices. All notices sent under this Agreement shall
be in writing and (i) hand delivered; (ii) transmitted by legible telecopy with a copy sent concurrently by certified mail, return receipt requested; or (iii) delivered by prepaid priority delivery service. Notices shall be sent to
the Parties at the following addresses or such other addresses as the Parties subsequently may provide: 
 If to ERYtech Pharma: 

ERYtech Pharma 
 60 Avenue
Rockefeller 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 Bâtiment Adenine 

69008 Lyon 
 France 

Phone: [***] 
 Fax: [***] 

Email: [***] 
 If to medac: 

medac GmbH 
 [***] 

Theaterstrasse, 6 
 22880 Wedel

 Germany 
 Phone: [***] 

Fax: [***] 
 Email: [***] 

A Party may change its address or numbers of service by notice to the other party. 

17.5 Force Majeure. Neither Party shall be liable to the other for the failure to perform, or a delay in performing, its obligations
under this Agreement by virtue of the occurrence of an event of Force Majeure. The Party affected by such Force Majeure event shall promptly notify the other Party and shall exert reasonable efforts to eliminate, cure or overcome such Force Majeure
event and to resume performance of its obligations hereunder. 
 In the event a Force Majeure event affecting either Party hereunder
continues for more than six (6) months the Party not subject to the Force Majeure event may terminate this Agreement upon written notice. 

17.6 Cumulative Remedies. The rights and remedies provided in this Agreement and all other rights and remedies available to either
Party at law or in equity are, to the extent permitted by law, cumulative and not exclusive of any other right or remedy now or hereafter available at law or in equity. Neither asserting a right nor employing a remedy shall preclude the concurrent
assertion of any other right or employment of any other remedy, nor shall the failure to assert any right or remedy constitute a waiver of that right or remedy. 

17.7 Amendment. This Agreement may be modified or amended only by written agreement of the Parties. 

17.8 Entire Agreement. This Agreement (including any exhibits hereto, all of which are incorporated herein by reference) constitutes
the entire agreement between the Parties concerning the subject matter of this Agreement. This Agreement supersedes all prior agreements between the Parties concerning the subject matter of this Agreement. 

17.9 Independent Contractor. The Parties are independent contractors. Nothing in this Agreement is intended or shall be deemed to
create an association, partnership, joint venture, agency or employer and employee relationship between the Parties, or to authorize either Party to act as agent for the other or to enter into contracts on behalf of the other. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 17.10 Assignment. Neither Party shall assign to a Third Party any portion of this
Agreement without the written approval of the other Party. However, ERYtech Pharma may, without consent, assign this Agreement to a purchaser of the entire company (Affiliate) or of the unit to which the Product pertains. 

17.11 Binding Effect. All the provisions thereof shall inure to the benefit of and be binding upon the Affiliates of the Parties.

 17.12 Use of Trademark. Each Party hereby agrees that neither it nor any of its Affiliates shall use the name, logo, or any
other trademarks of any other Party. Each Party agrees that it may use its own trademarks for any purpose without obligation to the other Party. 

17.13 Severability. The provisions of this Agreement are deemed to be several and any invalidity of any provision of this Agreement
will not affect the validity of the remaining provisions of this agreement. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 IN WITNESS WHEREOF, the
Parties have caused this Agreement to be executed by their duly authorized officers. 
  

			
	ERYtech Pharma
		
	By:	 	 /s/ Mr. Pierre-Olivier Goineau

	Name:	 	Mr. Pierre-Olivier Goineau
	Title:	 	Chief Executive Officer
	
	Place and date: Lyon, April 8th 2011
	
	medac
		
	By:	 	 /s/ Nikolaus Graf Stolberg

	Name:	 	Nikolaus Graf Stolberg
	Title:	 	Managing Director
	
	Place and date: Wedel, 3.5.2011
	
	medac
		
	By:	 	 /s/ Dr. Michaela Rehberg

	Name:	 	ppa. Dr. Michaela Rehberg
	Title:	 	 Director Drug Regulatory Affairs /

Pharmaceutical Development

	
	Place and date: Wedel, 03.05.2011

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 EXHIBIT 1: SPECIFICATIONS 

 

					
	 RELEASE
SPECIFICATIONS

	[***]	  	[***]	  	[***]
	[***]	  		  	
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  		  	
	[***]	  	[***]	  	[***]
	[***]	  		  	
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  		  	
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 EXHIBIT 2: ANNUALLY AND QUATERLY FORECASTS 

Nber of Vials to be ordered and delivered for clinical trials 

[***] 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 EXHIBIT 3: GRASPA INDICATIONS 

 

	•	 	For the Clinical and the Routine Supply: 

 [***] 

This list could be extended in writing as an amendment to this Agreement. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 ADDENDUM NO 1 TO 

EXCLUSIVE SUPPLY AGREEMENT 

for recombinant L-Asparaginase 
 This
Addendum is entered between: 
 ERYTECH PHARMA S.A, a company incorporated under the laws of the Republic of France
(n° 479 560 013 RCS Lyon), having its registered head office at Bâtiment Adenine, 60 avenue Rockefeller, 69008 Lyon, France, represented by Mr. Pierre-Olivier Goineau, Chief Operating Officer, (VAT No. FR 10479560013) and by
Mr. Gil Beyen, Chairman, hereinafter referred to as “ERYTECH Pharma” and MEDAC GMBH, a company having its registered head office at Theaterstrasse 6, D-22880 Wedel, Germany
represented by Nikolaus Graf Stolberg, Managing Director and Dr. Michaela Rehberg, Director Drug Regulatory Affairs/Pharmaceutical Development (VAT No. DE 118579535), hereinafter referred to as “medac,” hereinafter
referred to individually or collectively as the “Parties” and individually as a “Party”. 

WHEREAS, the Parties have signed an Exclusive Supply Agreement on
3rd May 2011 (hereinafter “the Agreement”). The Agreement deals with GRASPA® which is a trademark of ERY-ASP.
From the date of signature of this Addendum, the term “GRASPA®” used in the Agreement shall be read “ERY-ASP”. 

According to the Article 4.1.1 of the Agreement, the Parties agree to determine the Norm scale price for clinical purposes, no later than
[***]. 
 Therefore, after having discussed the above-mentioned provisions during several Steering Committees from October 1st 2013, the Parties decide to amend the Articles 4.1.1 of the Agreement, to read as follows: 

ARTICLE IV. 
 PRICES AND
EXCLUSIVITY 
 4.1 Price. ERYTECH Pharma shall purchase the Product and medac will supply the Product with the terms and
conditions of the [***]. 
 4.1.1 Clinical Supply. The price for supply will be: 

 

	 	•	 	Pilot scale: 

  

	 	•	 	€ [***] / vial [***] € [***]/vial for [***] to be ordered from the date of signature of this Addendum 

  

	 	•	 	Norm scale: 

  

	 	•	 	€ [***] / vial (hereinafter referred to as “Norm scale price”). 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 This is the price for clinical trial purposes only. At the request of medac the Norm scale
price could be rediscussed between the Parties from the [***] vial supplied at the Norm scale price. 
 Except as otherwise provided herein,
all terms and conditions of the Article 4 (from 4.1.2 to 4.3) shall remain in full force and effect. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 IN WITNESS WHEREOF, the
Parties have caused this Agreement to be executed by their duly authorized officers. 
  

			
	ERYTECH Pharma
		
	By:	 	 /s/ Mr. Pierre-Olivier Goineau

	Name:	 	Mr. Pierre-Olivier Goineau
	Title:	 	Chief Operating Officer
	
	Place and date: Hamburg, 4/4/2014
	
	ERYTECH Pharma
		
	By:	 	 /s/ Mr. Gil Beyen

	Name:	 	Mr. Gil Beyen
	Title:	 	Chairman
	
	Place and date: Hamburg, 4.4.2014
	
	Medac
		
	By:	 	 /s/ ppa. Dr. Michaela Rehberg

	Name:	 	Dr. Michaela Rehberg
	Title:	 	Director Drug Regulatory Affairs / Pharmaceutical Development
	
	Place and date: 4.4.2014
	
	Medac
		
	By:	 	 /s/ Nikolaus Graf Stolberg

	Name:	 	Nikolaus Graf Stolberg
	Title:	 	Managing Director
	
	Place and date: Hamburg, 4.4.2014

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]